{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:35:45Z","timestamp":1761561345885,"version":"build-2065373602"},"reference-count":19,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T00:00:00Z","timestamp":1244160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrespiratorymedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORMJ"],"published-print":{"date-parts":[[2009,6,5]]},"abstract":"<jats:p>Many drugs may cause toxic injury to the lungs and the pleura. Cabergoline is an ergoline derivative which has been used in Spain for seven years to control symptoms of Parkinson\u2019s disease. We report a patient with dyspnea, bilateral pleural effusion and distal swelling. After a series of complementary tests (blood analysis, chest CT, echocardiogram, pleural tap, pleural biopsy), etiological screening ruled out infection, malignancy or inflammation. Given the patient\u2019s history of three years\u2019 treatment with cabergoline, the drug was considered a possible cause and was progressively withdrawn. The patient\u2019s clinical condition improved and radiological images were disease-free. Using Karch and Lasagna\u2019s classical criteria, we defined a relationship of \u201cprobable causality\u201d between the drug and the adverse effects reported.<\/jats:p>","DOI":"10.2174\/1874306400903010090","type":"journal-article","created":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T12:18:44Z","timestamp":1244463524000},"page":"90-93","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pleuropulmonary Toxicity of Another Anti-Parkinson\u2019s Drug: Cabergoline"],"prefix":"10.2174","volume":"03","author":[{"given":"Yolanda","family":"Belmonte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriol de","family":"F\u00e0bregues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","unstructured":"John HT, Sahn A. \n            \n            Clinics in Chest Medicine.  \n            Philadelphia: WB Saunders Co 2004; 25: pp. \n            \n            \n            \n            141-53.","DOI":"10.1016\/S0272-5231(03)00125-4"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1157\/13109474","volume":"43","author":"Villavicencio C","year":"2007","unstructured":"Villavicencio C, Ramirez-Sarmiento A, Gayete A, Santiago G, Orozco-Levi M. \n            Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug \n            Arch Bronconeumol  \n            2007; \n            43\n            : 519-22.","journal-title":"Arch Bronconeumol"},{"journal-title":"Ministerio de Sanidad y Consumo. Ref: 2007\/06.20 April","year":"2007","key":"refR3","unstructured":"Comunicaci\u00f3n sobre riesgos de medicamentos para profesionales sanitarios. Cabergolina y riesgo de valvulopat\u00eda cardiaca \n            Ministerio de Sanidad y Consumo Ref: 2007\/0620 April \n            2007."},{"key":"refR4","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0954-6111(98)90415-2","volume":"92","author":"Comet R","year":"1998","unstructured":"Comet R, Domingo C, Such JJ, Ribera G, Sans J, Marin A. \n            Pleuropulmonary disease as a side-effect of treatment with bromocriptine \n            Respir Med  \n            1998; \n            92\n            : 1172-4.","journal-title":"Respir Med"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"Roth BL","year":"2007","unstructured":"Roth BL. \n            Drugs and valvular heart disease \n            N Engl J Med  \n            2007; \n            356\n            : 6-9.","journal-title":"N Engl J Med"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt1977213247","volume":"21","author":"Karch FE","year":"1997","unstructured":"Karch FE, Lasagna L. \n            Towards the operational identification of adverse drug reactions \n            Clin Pharmacol Ther  \n            1997; \n            21\n            : 247-54.","journal-title":"Clin Pharmacol Ther"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00702-005-0289-1","volume":"112","author":"Dhawan V","year":"2005","unstructured":"Dhawan V, Medcalf P, Stegie F, et al. \n            Retrospective evaluation of cardio-pulmonary fibrotic side effect in symptomatic patients from a group of 234 Parkinson\u2019s disease patients treated with cabergoline \n            J Neural Trans  \n            2005; \n            112\n            : 661-8.","journal-title":"J Neural Trans"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"Kvernmo T","year":"2006","unstructured":"Kvernmo T, H\u00e4rtter S, Burger E. \n            A review of the receptor-binding and pharmacokinetic properties of dopamine agonists \n            Clin Ther  \n            2006; \n            28\n            : 1065-78.","journal-title":"Clin Ther"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1378\/chest.120.1.313","volume":"120","author":"Danoff SK","year":"2001","unstructured":"Danoff SK, Grasso ME, Terry PB, Flymm JA. \n            Pleuropulmonary disease due to pergolide use for restless legs syndrome \n            Chest  \n            2001; \n            120\n            : 313-6.","journal-title":"Chest"},{"key":"refR10","unstructured":"Butllet\u00ed de Farmacovigil\u00e0ncia de Catalunya. Valvulopaties per pergolida i cabergolina. Gener-Febrer \n            Generalitat de Catalunya Departament de Salut  \n            2007; \n            vol. 5\n            (1)"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.revmed.2004.01.004","volume":"25","author":"Ciubutaru V","year":"2004","unstructured":"Ciubutaru V, Poinsignon Y, Brunet-Bourgin F, Mestassi M, Rosenbaum D. \n            Severe pleuropericarditis induced by long-term bromocriptine therapy, report of a case and review of the literature \n            Rev Med Interne  \n            2004; \n            25\n            : 310-4.","journal-title":"Rev Med Interne"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.410300416","volume":"30","author":"Bhatt MH","year":"1991","unstructured":"Bhatt MH. \n            Pleuropulmonary disease associated with dopamine agonist therapy \n            Ann Neurol  \n            1991; \n            30\n            : 613-.","journal-title":"Ann Neurol"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1183\/09031936.93.05020263","volume":"5","author":"Frans E","year":"1992","unstructured":"Frans E. \n            Pleuropulmonary changes during treatment of Parkinsons\u2019s disease with a long-acting ergot derivate, cabergoline \n            Eur Respir J  \n            1992; \n            5\n            : 263-5.","journal-title":"Eur Respir J"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/74.4.371","volume":"74","author":"Ling LH","year":"1999","unstructured":"Ling LH. \n            Constrictive pericarditis and pleuropulmonary disease to ergot dopamine agonist therapy (cabergoline) for Parkinson\u2019s disease \n            Mayo Clin Proc  \n            1999; \n            74\n            : 371-5.","journal-title":"Mayo Clin Proc"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1034\/j.1399-3003.1999.14d40.x","volume":"14","author":"Frank W","year":"1999","unstructured":"Frank W. \n            Low dose cabergoline induced intersticial pneumonitis \n            Eur Respir J  \n            1999; \n            14\n            : 968-70.","journal-title":"Eur Respir J"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1136\/hrt.2004.036236","volume":"90","author":"Townsend M","year":"2004","unstructured":"Townsend M. \n            Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson\u2019s disease \n            Heart  \n            2004; \n            90\n            : e47.","journal-title":"Heart"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejim.2004.09.014","volume":"16","author":"Guptha SH","year":"2005","unstructured":"Guptha SH. \n            Pleural effusion and thickening due to cabergoline use in a patient with Parkinson\u2019s disease \n            Eur J Intern Med  \n            2005; \n            16\n            : 129-31.","journal-title":"Eur J Intern Med"},{"key":"refR18","first-page":"614","volume":"64","author":"Shuji H","year":"2006","unstructured":"Shuji H. \n            Cebergoline-induced pleural effusion in an elderly patient with Parkinson\u2019s disease \n            Neurol Med  \n            2006; \n            64\n            : 614-9.","journal-title":"Neurol Med"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874306400701010001","volume":"1","author":"Domingo C","year":"2007","unstructured":"Domingo C, Roig J. \n            Neglected respiratory toxicity caused by cancer therapy \n            Open Respir Med J  \n            2007; \n            1\n            : 1-6.","journal-title":"Open Respir Med J"}],"container-title":["The Open Respiratory Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V03\/TORMJ-3-90\/TORMJ-3-90.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V03\/TORMJ-3-90\/TORMJ-3-90.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V03\/TORMJ-3-90\/TORMJ-3-90.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:22:08Z","timestamp":1761549728000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrespiratorymedicinejournal.com\/VOLUME\/03\/PAGE\/90\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,5]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,6,5]]}},"alternative-id":["TORMJ-3-90"],"URL":"https:\/\/doi.org\/10.2174\/1874306400903010090","relation":{},"ISSN":["1874-3064"],"issn-type":[{"type":"print","value":"1874-3064"}],"subject":[],"published":{"date-parts":[[2009,6,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2008-8-1","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-11-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-5-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}